CervoMed Inc (CRVO) Stock Forecast & Price Target

CervoMed is viewed favorably because neflamapimod is showing a compelling mechanistic and clinical rationale in DLB, where biomarker and MRI findings suggest effects on the underlying disease process rather than only symptomatic benefit. The 159-patient Phase 2b RewinD-LB program produced durable basal forebrain volume stabilization over 48 weeks, while newer PK/PD work supports a more effective 100mg BID regimen with higher trough exposure and lower peak exposure, aligning efficacy with tolerability. Near-term nfvPPA readouts from the ongoing Phase 2a trial (n=25), plus FDA removal of the plasma exposure limit and improved manufacturing consistency, further reduce development risk and strengthen the case for pivotal advancement.

CervoMed is a clinical-stage company whose valuation rests heavily on neflamapimod, yet the model still assigns only a 50% probability of approval in early-stage DLB, underscoring substantial binary clinical and regulatory risk. The investment case is further weakened by uncertainty around timely Phase 3 initiation, the possibility of disappointing pivotal data, slower-than-expected uptake, and medium-term dilution risk. Although it held $24.9M in cash, cash equivalents, and marketable securities at mid-2026 and expects funding through 3Q27, the company remains loss-making with a 2Q26 net loss of $0.64 per share and projected full-year 2026 and 2027 losses of $2.32 and $1.90 per share, respectively.